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Age and origin of major Smith-Lemli-Opitz syndrome (SLOS)
mutations in European populations
Abstract
BACKGROUND: Smith-Lemli-Opitz syndrome (SLOS) (MIM 270 400) is an autosomal recessive
multiple congenital anomalies/mental retardation syndrome caused by mutations in the Delta7-sterol
reductase (DHCR7, E.C.1.3.1.21) gene. The prevalence of SLOS has been estimated to range between
1:15000 and 1:60000 in populations of European origin. METHODS AND RESULTS: We have
analysed the frequency, origin, and age of DHCR7 mutations in European populations. In 263 SLOS
patients 10 common alleles (c.964-1G>C, p.Trp151X, p.Thr93Met, p.Val326Leu, p.Arg352Trp,
p.Arg404Cys, p.Phe302Leu, p.Leu157Pro, p.Gly410Ser, p.Arg445Gln) were found to constitute
approximately 80% of disease-causing mutations. As reported before, the mutational spectra differed
significantly between populations, and frequency peaks of common mutations were observed in
North-West (c.964-1G>C), North-East (p.Trp151X, p.Val326Leu) and Southern Europe (p.Thr93Met).
SLOS was virtually absent from Finland. The analysis of nearly 8000 alleles from 10 different European
populations confirmed a geographical distribution of DHCR7 mutations as reported in previous studies.
The common Null mutations in Northern Europe (combined ca. 1:70) occurred at a much higher
frequency than expected from the reported prevalence of SLOS. In contrast the most common mutation
in Mediterranean SLOS patients (p.Thr93Met) had a low population frequency. Haplotypes were
constructed for SLOS chromosomes, and for wild-type chromosomes of African and European origins
using eight cSNPs in the DHCR7 gene. The DHCR7 orthologue was sequenced in eight chimpanzees
(Pan troglodytes) and three microsatellites were analysed in 50 of the SLOS families in order to estimate
the age of the three major SLOS-causing mutations. CONCLUSIONS: The results indicate a time of
first appearance of c.964-1G>C and p.Trp151X some 3000 years ago in North-West and North-East
Europe, respectively. The p.Thr93Met mutations on the J haplotype has probably first arisen
approximately 6000 years ago in the Eastern Mediterranean. Together, it appears that a combination of
founder effects, recurrent mutations, and drift have shaped the present frequency distribution of DHCR7
mutations in Europe.
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Abstract 
 
Background: 
Smith-Lemli-Opitz Syndrome (SLOS [MIM 270 400] is an autosomal recessive multiple 
congenital anomalies/mental retardation syndrome caused by mutations in the ∆7-sterol 
reductase (DHCR7, E.C.1.3.1.21) gene. The prevalence of SLOS has been estimated to 
range between 1:15000 and 1:60000 in populations of European origin. We have analyzed 
the frequency, origin, and age of DHCR7 mutations in European populations.  
Methods and Results: 
In 263 SLOS patients ten common alleles (c.964-1G>C, p.Trp151X, p.Thr93Met, 
p.Val326Leu, p.Arg352Trp, p.Arg404Cys, p.Phe302Leu, p.Leu157Pro, p.Gly410Ser, 
p.Arg445Gln) were found to constitute approximately 80% of disease-causing mutations. As 
reported before, the mutational spectra differed significantly between populations and 
frequency peaks of common mutations were observed in North-West (c.964-1G>C), North-
East (p.Trp151X, p.Val326Leu) and Southern Europe (p.Thr93Met). SLOS was virtually 
absent from Finland. The analysis of nearly 8000 alleles from ten different European 
populations confirmed a geographical distribution of DHCR7 mutations as reported in 
previous studies. The common Null mutations in Northern Europe (combined ca. 1:70) 
occurred at a much higher frequency than expected from the reported prevalence of SLOS. 
In contrast the most common mutation in Mediterranean SLOS patients (p.Thr93Met) had a 
low population frequency. Haplotypes were constructed for SLOS chromosomes, and for 
wild-type chromosomes of African and European origins using eight cSNPs in the DHCR7 
gene. The DHCR7 orthologue was sequenced in eight chimpanzees (Pan Troglodytes) and 
three microsatellites were analyzed in 50 of the SLOS families in order to estimate the age of 
the three major SLOS causing mutations.  
Conclusion: 
The results indicate a time of first appearance of c.964-1G>C and p.Trp151X some 3000 
years ago in North-West and North-East Europe respectively. The p.Thr93Met mutations on 
the J haplotype has probably first arisen approximately 6000 years ago in the Eastern 
Mediterranean. Together, it appears that a combination of founder effects, recurrent 
mutations, and drift have shaped the present frequency distribution of DHCR7 mutations in 
Europe. 
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Introduction 
 
Smith-Lemli-Opitz/RSH Syndrome (SLOS) [MIM 270400] is an autosomal recessive 
metabolic malformation disorder with an estimated prevalence of 1:15000 to 1:60000 in 
European populations [1-4]. The syndrome is thought to be rare in non-European populations 
[5]. SLOS is characterized by a variable combination of malformations, dysmorphic signs and 
mental retardation including growth retardation, microcephaly, male genital anomalies, 
postaxial polydactyly and 2/3 syndactyly of the toes. The clinical severity of SLOS ranges 
from intrauterine lethality to mild dysmorphisms and moderate mental impairment [3]. 
A breakthrough in the understanding of the aetiology and pathogenesis of SLOS was the 
demonstration that the disease is caused by an error in the biosynthesis of cholesterol [6-7]. 
Mutations in the ∆7-sterol reductase (DHCR7) which catalyzes the last step of cholesterol 
biosynthesis were identified in all patients with biochemically confirmed SLOS [8-11]. The 
mutational spectrum of the DHCR7 gene has since been determined in a large number of 
SLOS patients [12-14]. In total more than 100 DHCR7 gene mutations have been described, 
of which a few are considerably more frequent than others [15]. The four most common 
mutations identified in SLOS patients of European and European-American ancestry are two 
Null mutations c.964-1G>C and p.Trp151X, which are associated with the most severe 
phenotype and two missense mutations p.Val326Leu and p.Thr93Met which are associated 
with a less severe phenotypes [14,16]. So far, little is known about the incidence of SLOS in 
Africa or Asia [5,12,17,18] but patients from the Middle East have been described [19]. 
In order to explain the relatively high prevalence of SLOS in North-East Europe a 
heterozygote advantage has been postulated for carriers of DHCR7 mutations. The role of 
cholesterol in the metabolism of bile acid, steroid hormones, myelin, and vitamin D is well 
understood and points towards the possible nature of such a selective advantage [20]. It is 
worthy of note that the high frequency in Europe of the common cystic fibrosis-causing 
mutation ∆F508 in the CFTR gene was likewise explained by balancing selection due to the 
probable protection against bronchial asthma [21,22].  
In the present study we have estimated the carrier frequencies of DHCR7 mutations c.964-
1G>C, p.Trp151X and p.Thr93Met in several different European populations (Austrian, 
German, Italian, Polish, British, French, Spanish, Czech, Greek, Turkish), constructed SNP 
haplotypes by the analysis of core families of European and African origin, sequenced the 
DHCR7 orthologue in chimpanzees and finally tried to estimate the age of c.964-1G>C, 
p.Trp151X, and p.Thr93Met in an attempt to understand the cause of the geographic 
frequency gradients and high incidence of SLOS exclusively seen in Europe.  
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Subjects and Methods 
 
DNA Samples 
For mutation analysis and SNP haplotyping of the DHCR7 gene 187 SLOS patients from 157 
affected families and 106 singleton SLOS patients from Austria, Argentina, Canada, 
Denmark, Finland, Germany, Greece, Ireland, Italy, Lebanon, Lithuania, Poland, Spain, 
Switzerland, Turkey, the United Kingdom, and the United States were analyzed following 
informed consent resulting in a total of 263 independent SLOS patients. Mutations in 168 of 
these have been reported previously [8,14,23,24]. Eight patients from Finland diagnosed with 
SLOS based on elevated 7DHC and mental retardation have also been included for mutation 
analysis [25]. For haplotype analysis in Africans nine Gabonese families have been analysed 
following informed consent.  
The age of a given mutation was estimated by analysis of 15 SLOS patients for c.964-1G>C, 
22 SLOS patients for p.Trp151X and of 15 SLOS patients for p.Thr93Met and their parents. 
The coding regions of the DHCR7 orthologue, including all exon-intron boundaries, were 
sequenced in nine DNAs from Pan troglodytes (Immuno AG, Vienna, Austria). Population-
based DNA samples originated from Austria (Tyrol, n=700 unrelated blood donors), Germany 
(Berlin, n=500 unrelated blood donors), Italy (n=500 blood donors and unrelated donors), 
Poland (Warsaw, n=500 newborn screening for cystic fibrosis), the UK (London, n=288 
healthy controls of Northwick Park Heart Study II), France (Toulouse, n=250 unrelated blood 
donors), Spain (n=345 unrelated blood donors from Barcelona and n=400 samples from the 
Spanish DNA bank), Czech Republic (n=500 individuals collected for heterozygote detection 
of recessive diseases), Greece (n=416 newborns from thalassemia screening), Turkey 
(n=274 unrelated control samples), all obtained after informed consent. The African samples 
(61 South African Blacks, 60 Khoi San, 122 Egyptians, and 98 Gabonese) have been 
collected for epidemiological studies and have been published elsewhere [26,27]. All 
samples and data were completely anonymized.  
 
DNA Extraction 
DNA was extracted from EDTA blood samples or from Guthrie cards as described. The 
African DNA samples were stored as plugs in agarose gels and were extracted using 
established procedures [28]. Extraction from Guthrie cards and agarose plugs was 
performed successfully using appropriate kits from Qiagen and the fully automated 
Genovision M 48 (Quiagen). 
 
 
 
Amplification Reactions 
The complete coding sequence of the DHCR7 gene of SLOS patients was sequenced using 
previously published primers [8]. Sequencing was performed with ABI310 and 3130xl 
Genetic Analyzer using BigDye version 1.1.  
 
SNP Haplotyping 
DHCR7 SNP 189, 207, 231 and 1272 genotyping was performed with TaqMan probes and 
end-point analysis with the ABI 7000 SDS.  
 
SNP for primer 5´-3´ rev primer 5´-3´ mut probe-MGB 
5´-3´-FAM 
WT probe-MGB 
5´-3´-VIC 
189 cccccttcatcgtctactacttca ccggtcagggcgca ttgtgaccagtacagc ttgtgaccaatacagct 
207 ccccttcatcgtctactacttcatc ccgagagccgagcatgtc ctgactggccctgtg ctgaccggccctg 
231 ctgaccggccctgtggt tataggtggagtcttggccca catcgtcactggacat catcgtcaccggacat 
1272 gacctgatgggcagcctg tgtagatgatgtagaagtagggcagc aggtggccgccgc tggccaccgccac 
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Allele-specific PCRs for DHCR7 SNPs 207 and 438 were performed using the following 
primers: 207for: 5´ - gcctcttagggtcctggtg - 3´, 207revmut: 5´ - atgtccaccacagggcca - 3´, 
207revWT: 5´- atgtccaccacagggccg - 3´, 438formut: 5´ - gaacaagtatcagatcaacggt - 3´, 
438forWT: 5´ - gaacaagtatcagatcaacggc - 3´, 438rev: 5´ - ataccagtctctggcgctgg - 3´. PCR 
products were analyzed by agarose gel electrophoresis. Haplotypes were constructed from 
parental genotypes or deduced in compound heterozygotes for c.964-1G>C by assigning 
haplotype A to the c.964-1G>C mutation. Haplotype A for c.964-1G>C was constructed for 
31 chromosomes from 25 trios and 6 homozygous patients. Haplotype IDs were as 
previously described in [23,29]. Two newly detected haplotypes (GTCTTC) and (ACCTTT) 
were denoted as K and P respectively. 
 
Population Screening 
Mutation-specific PCRs were performed in 96 well-microplates using specific primers 
p.Trp151X: W151Xfor: 5´ - tca acg gcc tgc aag ccc a - 3´, 6R [8], c.964-1G>C: IVSfor: 5´ - 
ccc ctc gcc ccc cac - 3´, 95ASOrev: 5´ - cgg gcc acg ccc cag aag - 3´, and p.Thr93Met: 4F 
[8], TArev: 5´ - agc tgg gcg gct ttc ctt a – 3´. The PCR conditions were denaturation at 95°C 
for 5 min, followed by 35 cycles consisting of 45 sec each at 95 °C, 60 °C, and 72 °C, and a 
final step at 72 °C for 10 min. 50 ng DNA were usually used for each PCR. PCRs were 
performed with Quiagen Taq Polymerase. In all PCRs amplicons of exon 10 of the RET 
protooncogene (CRT19E, CRT19F) were used as a positive control [30]. 
 
 
Microsatellite Analysis 
Microsatellites D11S4139, D11S1314, D11S4119 were amplified by PCR using published 
primer sequences (NCBI UniSTS). Allele sizes are 151-195 bp, 209-227 bp, and 151-169 bp 
for D11S4139, D11S1314, D11S4119 respectively. PCR products were analysed on 
denaturing 6% sequencing gels by silver staining [31]. Allele size here was estimated by 
comparing all PCR products belonging to one mutation (c.964-1G>C, p.W151X, or p. T93X) 
for age estimation. 
 
Statistical Analysis 
Allele frequencies were estimated by counting and 95% confidence intervals (CI) were 
determined on the basis of the binomial distribution.  
The expected homozygosity (h) at the DHCR7 locus was determined by h = Σxi2, where xi is 
the frequency of the ith allele in a given population. Ascertainment of mutations was assumed 
to be 100% in all population [32]. 
 
 
80183  81025  82101         83704 84341 kb (physical map) 
 77.53  78.13  78.74         80.88 81.07 cM (DeCODE) 
 
 
 D11S4139   D11S1314        D11S4207 D11S4119 
 
 
 
 
 
 
 
 
 
 
DHCR7 
11q13 
 
1158CT 
13.94 kb 
189A 438CT 207CT 
1      2                            3       4                   5         6                     7       8                        9 
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Figure 1 Scheme of the DHCR7 gene. Six SNPs used for haplotype construction and four 
flanking microsatellites D11S4139, D11S1314, D11S4207, D11S4119 used for age estimation are 
indicated. Exons (black boxes) are denoted by numbers (1-9). At the top the distances of 
microsatellites from the gene are indicated according to the physical and the recombination maps. 
 
 
Estimation of Mutation Age 
The method of mutation age estimation was applied on frequency data of microsatellites 
localized beside the DHCR7 gene (figure 1). For this analysis we considered only SLOS 
patients and their parents which had c.964-1G>C on haplotype A, p.Trp151X on haplotype F, 
and p.Thr93Met on haplotype J. The fraction of mutation-carrying chromosomes harboring 
the full-length founder haplotype decreases at a rate of 1 – θ per generation, where θ is the 
recombination rate corresponding to the genetic distance in question. After g generations, 
the expected relative frequency of a complete (i.e. non-recombined) founder haplotype will 
be P = (1–θ)g. For smallθ, the age g of the founder haplotype can be estimated using 
equation ln P = −θg [Eq.1]. However, the real proportion of recombinants, corresponding to 
(1-P), differs from the observed one, R, in such a way that R = (1-P)(1-pn), where pn is the 
frequency of the linked allele on normal chromosomes. The observed proportion of 
recombinant haplotypes is R = 1-pd, where pd is the frequency of the linked allele on disease 
chromosomes. Substituting P = (pd-pn)/(1-pn) into Eq. 1, we obtain -ln [(pd-pn)/(1-pn)] = θg [Eq. 
2], from which g, the age of the founder haplotype, can be estimated  by pair-wise analysis of 
the flanking marker alleles associated with the disease mutation [33]. 
If a population grows rapidly [34-36], the number of generations since the founder haplotype 
first arose would be better approximated by adding correction term g0 to the above estimate 
[37,38]. This term equals g0 = −d-1 ln[rfd /(1+rfd)] (Eq.3), where fd = ed/(ed–1) in a population 
growing at rate d per generation.  For this Luria-Delbrück-type of correction for population 
growth d=0.041 and d=0.02 were used depending upon the mutation type (for explanation 
see the results section).  
 
 
Results
 
 
DHCR7 Mutations in SLOS Patients and Population Comparison of Mutational Heterogeneity  
After sequencing the genomic region of the DHCR7 gene in 263 SLOS patients we were able 
to define mutational spectra according to the geographic origin of the patients (Table 1). Only 
mutational spectra from geographic regions with more than 10 patients are described. In all 
SLOS patients groups except the Polish the most common mutation was c.964-1G>C with an 
overall frequency of 35%. The other common mutation p.Trp151X is also a Null mutation. 
Mutations with a population-specific predominance were p.Thr93Met mutation in Italy and 
Spain, p.Val326Leu in Germany and Poland, p.Arg352Trp and p.Leu157Pro in Poland, and 
p.Phe302Leu and p.Gly410Ser in Spain confirming previous studies [11,16,24,39]. 
In order to evaluate the extent of allelic variation at the DHCR7 locus in Europe we 
calculated the relative number of different mutations and the expected homozygosity (h) in 
each population (Table 1). The most diverse spectrum of mutations was found in Italian 
SLOS patients with 16 different mutations found in 40 disease alleles (a ratio of 0.4 
mutations per allele). Particularly low levels of diversity were found in Polish patients. 
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Table 1 
Relative frequencies of the most frequent mutations, number of mutations per allele, and 
homozygosity of common DHCR7 gene mutations in  
SLOS patients from European populationsa as a measure of genetic heterogeneity.  
aincludes patients from Fitzky et al., 1998, Witsch-Baumgartner et al., 2000, Witsch-Baumgartner et 
al., 2001, Witsch-Baumgartner et al., 2005 
bonly of European origin 
cthis mutation was observed in 5 of 9 french/canadian alleles 
dno. of mutations means all different mutations observed in the corresponding population sample 
emutations per allele means the ratio of mutations to alleles investigated 
 
 
SLOS in Finland 
We also included eight Finnish patients in our analysis [25]. Although SLOS is reportedly 
very rare in Finland (H. H. Kääriäinen, personnel communication) seven patients with 
elevated cholesterol precursors 7DHC and 8DHC in their plasma were detected by a 
biochemical screening of patients with developmental disabilities. An additional patient was 
 United 
Kingdom 
France Germany Poland Italy Spain United 
Statesb 
Over all 
no. of 
chromosomes 
79 108 86 56 40 54 114 537 
c.964-1G>C 47% 46% 30% <5% 23% 33% 39% 35% 
p.Trp151X <5% 6% 17% 29% <5% <5% 10% 10% 
p.Thr93Met <5% <5% <5% <5% 28% 17% 9% 8% 
p.Val326Leu <5% <5%  9% 30% no no 5% 7% 
p.Arg404Cysc 5% <5% <5% no 8% no <5% <5% 
p.Arg 352Trp <5% <5%  6% 7% <5% <5% <5% <5% 
p.Phe302Leu <5% <5% no no no 15% no <5% 
p.Leu157Pro no no <5% 8% no no no <5% 
p.Gly410Ser <5% <5% <5% no no 9% no <5% 
p.Arg 446Gln no <5% no no no <5% <5% <5% 
p.Arg 242His no <5% <5% no no no no <5% 
no. of mutationsd  27 39 22 13 16 15 24 81 
mutations per 
allelee 
0.35 0.36 0.26 0.23 0.40 0.28 0.21 0.15 
Σxi2 0.234 0.226 0.161 0.193 0.153 0.160 0.184 0.146 
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diagnosed clinically among children with features of SLOS and confirmed biochemically. All 
seven patients identified in the group with developmental disabilities were considered to 
represent mild cases of SLOS (SLOS type I) [25]. Mutation analysis revealed compound 
heterozygosity (p.Trp151X and p.Met59Arg) in the single patient with a clinical diagnosis of 
SLOS. No DHCR7 mutation was found in any of the seven biochemically defined patients 
despite a mutation detection rate of >98% by our method. We also considered the presence 
of Finnish founder mutation in the non-coding sequence of the DHCR7 gene as a possible 
cause of the patients´ phenotype. Under this assumption patients were expected to share the 
same DHCR7 haplotype. However haplotyping revealed at least four different haplotypes 
and all seven patients had two different haplotypes, which excludes a common Finnish 
founder mutation as the cause of the biochemical phenotype. The only known Finnish patient 
with SLOS confirmed clinically, biochemically and by mutation analysis was of mixed Finnish 
(mother) and Moroccan (father) origin.  Hence this patient is not Finnish by ancestry of both 
sides. We therefore conclude that SLOS is very rare in Finland. 
 
DHCR7 Haplotype Frequencies in Europeans and Africans 
To study the evolutionary history of the observed DHCR7 mutations we constructed SNP 
haplotypes around the mutations using the intragenic SNPs shown in Figure 1. 
We analyzed 43 wild type (WT) DHCR7 alleles from the parents of SLOS patients (Table 2).  
These individuals came from Austria, Germany, Poland, and Italy. Their haplotypes were 
derived by segregation analysis. Most of the European WT alleles carried the A haplotype. In 
36 African alleles from Gabon the most common haplotypes were B, F, and the Z haplotype. 
The remainder were A, C, J, K, D, S, T, U, and V haplotypes. Whereas 70% of European 
alleles carried one of two different haplotypes (A and F), five haplotypes (B, F, Z, C, J) were 
found to account for 70% of the African (Gabon) DHCR7 WT alleles. 
 
Table 2 
SNP Haplotype Frequencies in Europeans (AT: n=2, DE: n=10, PL: n=18, IT: n=13) and Africans 
(Gabonese)  
Haplotype 
nt position (cDNA) 
189 207 231 438 1158 1272 
Haplotype 
ID  
European 
n = 43 
African 
n = 36 
A   C   C   C   C   T 
G   C   C   C   C   T 
G   C   C   C   C   C 
A   C   C   C   T   C 
A   C   C   C   C   C 
G   C   T   C   C   C 
G   T   C   T   T   C 
A   C   T   C   C   T 
A   C   C   T   C   T 
G   T   C   C   C   C 
G   T   C   C   C   T 
A   C   C   C   T   T 
A   C   C   T   T   T 
A   C   T   C   C   C 
G   C   T   C   T   C 
G   T   C   T   C   C 
G   T   C   C   T   T 
A 
B 
F 
Z 
C 
J 
K 
D 
L 
M 
N 
O 
P 
S 
T 
U 
V 
0.47 
0.02 
0.23 
0 
0.07 
0.05 
0.02 
0 
0.02 
0.02 
0.02 
0.02 
0.02 
0 
0 
0 
0 
0.06 
0.25 
0.17 
0.14 
0.08 
0.08 
0.06 
0.06 
0 
0 
0 
0 
0 
0.03 
0.03 
0.03 
0.03 
 
 
 
Sequence Variations in Pan troglodytes 
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The coding region of the DHCR7 gene orthologue was sequenced in nine chimpanzees (Pan 
troglodytes) in order to assess the level of sequence divergence between the human and the 
chimpanzee DHCR7 genes. Table 3 lists the type and location of all detected sequence 
variations in relation to the human sequence. Only two non-synonymous changes 
(p.Ser264Gly and p.Gly424Ser) were detected. Together, the detected variation corresponds 
to a sequence similarity of 99.4% at the cDNA level (i.e. 9/1425 nucleotides are different) and 
99.6% at the protein level (2/475 amino acids are different). Only one polymorphism, at 
position c.507 in exon 6, was detected in the nine Pan sequences. In terms of the human 
polymorphic sites, the chimpanzee sequence corresponds to the Z haplotype, which has to 
be considered as the ancestral.  
 
Table 3 
 
Sequence variation in Pan Troglodytes in Comparison to the Human DHCR7 Sequence 
exon 4 4 4 4 4 6 6 6 7 9 9 9 9 9 9 9 9 
bp c.123 c.189 c.207 c.213 c.231 c.438 c.507 c.549 c.790* c.969 c.1158 c.1224 c.1266 c.1272 c.1273* c.1350 c.1353 
h. sapiens G A/G C/T T C/T C/T G C A G/A C/T C T T/C G C/A C 
p. troglodyt. A A C C C C A/G T G G T T C C A C T 
frequency in 
p. troglodyt. 
1 1 1 1 1 1 0.39 1 1 1 1 1 1 1 1 1 1 
n p.t. alleles 
analysed 
16 16 16 16 16 18 18 18 6 12 12 14 14 14 14 14 14 
* mutations are leading to amino acid changes p.Ser264Gly and p.Gly424Ser respectively 
 
Haplotypes Associated with SLOS-Causing Mutations 
Haplotypes of chromosomes bearing c.964-1G>C were deduced by core family analysis or 
on the basis of patient homozygosity. Haplotypes surrounding other common mutations were 
constructed by core family analysis or by assigning haplotype A to c.964-1G>C, if necessary 
(Table 4). The c.964-1G>C mutation was always found to be associated with haplotype A 
independently of the geographic origin of the allele. Five different haplotypes were found to 
harbour the p.Thr93Met mutation. Individuals carrying p.Thr93Met on an A haplotype came 
from Germany, the UK, Ireland and the US while patients with p.Thr93Met on a J haplotype 
came from Italy, Spain, Turkey, and also from the US. Mutations p.Thr93Met, p.Arg404Cys, 
p.Arg352Trp, p.Gly410Ser and p.Arg242His all affect CpG dinucleotides.  These mutations 
were found to be associated with more than one haplotype. Mutation p.Trp151X does not 
affect a CpG, but is nevertheless associated with two additional haplotypes, each found once 
in Polish patients. In total 147 disease alleles were analyzed with respect to their SNP 
haplotype. Some 48% of these SLOS alleles carried haplotype A, and 32% carried haplotype 
F. 
 
Table 4 
DHCR7 haplotypes associated with common SLOS mutations 
SLOS 
Mutation 
Frequency 
in 429 
SLOS 
alleles 
CpG no. of 
chromosomes 
investigated 
SNP Haplotype 
ID 
Ethnic Origin of the Allels 
(no of alleles) 
c.964-1G>C 32% no 31 A DE(7), PL(1), UK(5), US(7), ES(3), 
IT(4), FR(1), CH(2), AT(1) 
p.Trp151X 11% no 24 F 
 
B 
G 
PL(13), DE(3), AT(2), ES(1), FI(1), 
LT(1), IT(1) 
PL(1) 
PL(1) 
p.Thr93Met 9% yes 32 J 
A 
F 
B 
C 
IT(8), ES(8), TR(1), US(3) 
DE(2), UK(2), IE(1), US(3) 
IT(1), ES(1) 
DE(1) 
GR(1) 
p.Val326Leu 8% no 9 A DE(4), UK(1), IT(1), PL(1), US(2) 
p.Arg404Leu 4.7% yes 18 F 
A 
US(4), CN(1), UK(3), IT(1) 
FR(1), US(2), UK(1), IT(1) 
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B 
D 
FR(2) 
DE(1), US(1) 
p.Arg352Trp 4.5% yes 10 A 
F 
J 
PL(3), DE(2), US(1), UK(1) 
ES(1), IT(1) 
DE(1) 
p.Phe302Leu 2% no 7 F ES(6), UK(1) 
p.Leu157Pro 2% no 3 A DE(1), PL(1), LT(1) 
p.Gly410Ser 2% yes 8 A 
F 
ES(3), DE(1), UK(1) 
TR(3) 
p.Arg446Gln 1.2% no 2 A ES(2) 
p.Arg242HisH 0.9% yes 3 F 
A 
DE(2) 
DE(1) 
 
 
Carrier frequencies of the common DHCR7 mutations in Europeans 
Using allele-specific PCRs for common European SLOS mutations, samples from several 
different European populations were screened (Table 5). The combined carrier frequencies 
for c.964-1G>C and p.Trp151X was 1:100, 1:71 and 1:42 in the German, the Polish and the  
Czech population samples respectively. In the Mediterranean populations, higher 
frequencies for c.964-1G>C were observed in Italy (1:154) and Greece (1:161) than in Spain 
(1:318).  
Surprisingly the p.Thr93Met mutation which occurs at high frequency in SLOS alleles of 
Mediterranean origin was found only once in the Spanish and the Greek sample. Hence a 
precise frequency estimate can not be given for p.Thr93Met. 
None of the common Caucasian mutations (c.964-1G>C, p.Trp151X) could be detected in 
the African sample (South African blacks, Khoi San, Egyptians, and Gabonese). 
 
 
Table 5 
 
Allele Frequencies of Common DHCR7 Mutations in Europeans and Africans 
Mutation Population n1 Positive Allele frequencies [%]      95% CI[%]       Carrier frequency 
       
c.964-1G>C British  566 2 0.35 0.04 – 1.27 1:141 
 German (East) 1000 1 0.10 0.00 – 0.56 1:500 
 Austrian 1280 15 1.17          0.68 – 1.93  1:43 
 French  500 5 1.00 0.32 – 2.32 1:50 
 North Europeans 
 
Polish 
3346 
 
1000 
23 
 
1 
0.69 
 
0.10 
0.44 – 1.03 
 
0.00 – 0.56 
1:72 
 
1:500 
 Czech 
East Europeans 
 
Spanish 
Italian 
Greek 
Turkish 
1000 
2000 
 
1272 
922 
322 
182 
3 
4 
 
2 
3 
1 
0 
0.30 
0.2 
 
0.16 
0.33 
0.31 
0 
0.06 – 0.87 
0.05 – 0.51 
 
0.02 – 0.57 
0.07 – 0.95 
0.08 – 1.71 
0.00 – 2.0 
1:167 
1:250 
 
1:318 
1:154 
1:161 
0 
 South Europeans 
 
African* 
2698 
 
 624 
6 
 
0 
0.22 
 
0 
0.08 – 0.48 
 
0.00 – 0.76 
1:224 
 
0 
       
p.Trp151X German 1000 4 0.40 0.11 – 1.02 1:125 
 Austrian 1344 2 0.15 0.02 – 0.54 1:336 
 French  500 0 0 0.00 – 0.74 0 
 North Europeans 
 
Polish 
2844 
 
1000 
6 
 
6 
0.21 
 
0.60 
0.08 – 0.46 
 
0.22 – 1.31 
1:237 
 
1:83 
 Czech 
East Europeans 
 
Spanish 
Italian 
Greek 
1000 
2000 
 
1414 
866 
464 
9 
15 
 
0 
1 
1 
0.90 
0.75 
 
0 
0.12 
0.22 
0.41 – 1.70 
0.42 – 1.23 
 
0.00 – 0.26 
0.00 – 0.64 
0.01 – 1.2 
1:56 
1:67 
 
0 
1:433 
1:232 
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Turkish 186 0 0 0.00 – 1.96 0 
 South Europeans 
 
African* 
2930 
 
 678 
2 
 
0 
0.07 
 
0 
0.00 – 0.25 
 
0.00 – 0.53 
1:732 
 
0 
       
p.Thr93Met Austrian 1152 0 0    0.00 – 0.32 0 
    French 
   Spanish 
I  Italian 
   Greek 
Turkish 
   Europeans 
 
 500 
1056 
754 
800 
146 
4408 
  0 
  1 
  0 
  1 
  0 
  2 
0 
0.09 
0 
0.13 
0 
     0.05 
 
 
      0.00 – 0.74 
      0.00 – 0.53 
      0.00 – 0.49 
      0.00 – 0.69 
      0.00 – 2.49 
      0.00 – 0.16 
 
 
 
   0 
   1:528 
   0 
   1:400 
   0 
   1:1102 
p.Val326Leu    Austrian 1696   0 0  0.00 – 0.003     0 
 Polish 1000   0 0 0.00 – 0.37     0 
 Czech 1000   0 0 0.00 - 0.37               0  
       
 
1 number of chromosomes analysed 
* 61 South African Blacks, 60 Khoisan, 122 Egyptians, 98 Gabonese 
 
Estimation of the age of c.964-1G>C, p.Trp151X and p.Thr93Met  
The time of first appearance (i.e. age) of several frequent SLOS-causing mutations was 
estimated in an attempt to clarify whether natural selection may explain the higher 
prevalence of SLOS in populations of European descent, and the high frequency of Null 
mutations in some geographic regions. The p.Thr93Met mutation was found to be associated 
with several different SNP haplotypes (Table 4) and these haplotypes seem to be specific for 
particular geographic regions. Since all SLOS families with p.Thr93Met on the J haplotype 
originated from Mediterranean regions, the p.Thr93Met on this haplotype was included into 
the age estimation. Interlocus haplotype variation was assessed using microsatellite markers 
around the DHCR7 gene (Figure 1). The estimates of the age of different mutations are 
therefore subject to some variance, not only because of the small sample size and the 
unknown demography, but also because of the uncertainty about the microsatellites mutation 
rate and the inter-marker recombination rate.   
 
  D11S4139 D11S1314 D11S4119 
c.964-1G>C nb. of generations 80 53 62 
 
with d=0.041 130 99 83 
p.Thr93Met nb. of generations 122 140 No linkage with  
 
with d=0.02 195 206 mutation 
p.Trp151X nb. of generations 116 48 61 
 
with d=0.041 166 94 82 
 
The analysis of D11S4139 showed no allele frequency difference between wild-type and 
c.964-1G>C alleles (Table 6). Marker D11S1314 closest to the DHCR7 gene (0.61 cM) gave 
the most informative results for all three mutations.  
An adjustment factor of d=0.041 for Luria-Delbrück population growth correction was chosen 
for mutations c.964-1G>C and p.Trp151X because of the likely younger age of these 
mutations, inferred from the uncorrected results [40]. For p.Thr93Met d=0.02 was applied 
because of slower population growth in earlier history [40]. The results obtained with markers 
D11S1314 and D11S4119 suggest an age of 112 (corresponding to approximately 3400 
years) and 83 generations (2500 years), respectively for c.964-1G>C. The mean age of 100 
generations approximates to 3000 years. For p.Trp151X an age of 101 and 88 generations 
was calculated using D11S1314 and D11S4119 respectively, with an average of 95 
generations. This means that the mutation first arose approximately 2800 years (2600 – 
3000 years) ago. For the p.Thr93Met-J mutation, D11S4139 and D11S1314 yielded age 
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estimates of 195 and 206 generations respectively, with an average of 200 generations. This 
would correspond to 6000 years since its first appearance (5800 – 6200 years).  
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Table 6   
Frequency of microsallite alleles in SLOS patients with c.964-1G>C, p.Trp151X, and p.Thr93Met alleles and their parents 
  SLOS patients with 
c.964-1G>Ca,  n=15 
(2 homozygotes) 
Parents of SLOS 
patients with c.964-
1G>C 
SLOS patients with 
p.Trp151Xb, n=22 
(2 homozygotes) 
Parents of SLOS 
patients with 
p.Trp151X 
SLOS patients with 
p.Thr93Metc, n=15 
(1 homozygote) 
Parents of SLOS 
patients with 
p.Thr93Met 
Microsatellite 
marker 
Allele 
ID  
Mutated alleles, n (%) WT alleles, n (%) Mutated alleles, n (%) WT alleles, n (%) Mutated alleles, n (%) WT alleles, n (%) 
D11S4119 1 3 (17.6) 3 (0.1) 2 (11.1) 5 (17.9)  1 (5.3) 
 2 8 (47.1) 11 (36.7) 5 (27.8) 9 (32.1) 4 (28.6) 4 (21.1) 
 3 3 (17.6) 13 (43.3) 4 (22.2) 7 (25) 6 (42.9) 8 (42.1) 
 4 3 (17.6) 3 (0.1) 1 (5.6) 3 (10.7) 3 (21.4) 6 (31.6) 
 5   3 (16.7) - 1 (7.1)  
 6   1 (5.6) 2 (7.1)   
 7   0 2 (7.1)   
 sum 17  30 16 28 14 19 
D11S1314 1 - 6 (22.2) 18 (75) 6 (13.6)  1 (5) 
 2 - 1 (3.7) - 1 (2.3) 2 (16.7)  
 3 11 (73.3) 4 (14.8) 1 (4.2) - 6 (50) 5 (25) 
 4 1 (6.6) 4 (14.8) 1 (4.2) 9 (20.5) 1 (8.3) 5 (25) 
 5 1 (6.6) 6 (22.2) - 3 (6.8) 3 (25) 5 (25) 
 6 2 (13.3) 5 (18.5) - 8 (18.2)  4 (20) 
 7 - 1 (3.7) 2 (8.3) 10 (22.7)   
 8   2 (8.3) 7 (15.9)   
 sum 15 27 24 44 10 20 
D11S4139 1 1 (5.9) 4 (14.8) - 1 (2.9) 1 (6.7) 3 (14.3) 
 2  3 (11.1) 2 (11.1) 1 (2.9) 1 (6.7)  
 3 1(5.9) 2 (7.4) 1 (5.6) 2 (5.7) 8 (53.3) 8 (38.1) 
 4  1 (3.7) - 2 (5.7) 1 (6.7)  
 5 1(5.9)  - 1 (2.9) 2 (13.3) 3 (14.3) 
 6 1(5.9) 2 (7.4) - 2 (5.7) 1 (6.7)  
 7  3(11.1) 1 (5.6) 1 (2.9)  1 (4.8) 
 8   - 2 (5.7)  2 (9.5) 
 9 13 (76.5) 10 (37) - 3 (8.6)  1 (4.8) 
 10  1(3.7) - 1 (2.9)  1 (4.8) 
 11  1(3.7) 2 (11.1) 4 (11.4) 1 (6.7) 2 (9.5) 
 12   - 5 (14.3)   
 13   1 (5.6) 3 (8.6)   
 14   1 (5.6) 2 (5.7)   
 15   - 1 (2.9)   
 16   10 (55.6) 4 (11.4)   
 sum 17 27 18 35 15 21 
a
 origin of c.964-1G>C alleles: 10 German, 3 Spanish, 2 Italian, 1 British, 1 US 
b origin of p.Trp151X alleles: 16 Polish, 4 German, 2 Spanish, 1 Italian, 1 Lithuanian 
c
 origin of p.thr93Met alleles: 7 Spanish, 7 Italian, 1 Portugese, 1 Turkish
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Discussion 
 
Spectra of DHCR7 gene mutations in European SLOS Patients  
We have assessed the DHCR7 genotypes of more than 250 SLOS patients from different 
European countries. Some populations not represented here have previously been reported 
by others [13]. Ten different mutations account for approximately 80% of all SLOS alleles in 
our sample. Some of them are most frequent in specific regions, as is the case for c.964-
1G>C mutation in the UK, France, Netherlands (35% in 34 SLOS patients [13]), and 
Germany, the p.Trp151X and the p.Val326Leu mutations in Poland, and the p.Thr93Met 
mutation in Italy and Spain. Some mutations have frequencies >5% only in specific regions. 
This is the case for p.Arg352Trp in Poland, and for p.Phe302Leu and p.Gly410Ser in Spain. 
Notably only a single SLOS patient carrying DHCR7 mutations was identified in Finland. This 
patient was of mixed ancestry with the father being of Moroccan origin. The relative number 
of different mutations adjusted for sample size was higher in some populations than in 
others. A high mutational diversity was noted for SLOS patients from Italy, UK and France. In 
SLOS patients from Poland and the US, in contrast, only a few different mutations were 
detected. Homozygosity values calculated on the basis of disease allele frequencies in SLOS 
patients also indicated that German, Italian and Spanish populations are more 
heterogeneous than Polish and US American. A comparatively low mutational heterogeneity 
in Poland has also been described for phenylketonuria (PKU), for which diversity in the 
underlying PAH gene is again higher in Sicily and Germany [29]. The British and French 
samples were less heterogeneous with respect to DHCR7 genotype than other Europeans, 
mainly because of the high frequency of c.964-1G>C. Although 114 independent 
chromosomes of SLOS patients from the US were analyzed, they harboured only a small 
fraction of the DHCR7 alleles. As expected, the frequent US mutations (c.964-1G>C, 
p.Trp151X, p.Thr93Met) represented a mixture of the main mutations found in European 
populations that have migrated to North-America. The homozygosity value obtained for the 
US samples does also not match the expectation apt for such an ethnically heterogeneous 
population. The reason for this discrepancy may be post-migrational admixture of people 
from different European origins. 
 
Recurrent Mutations  
Our study has revealed that at least some SLOS-causing mutations in the DHCR7 gene are 
likely to be recurrent. For instance, p.Arg404Cys was first reported in a consanguineous 
family of French origin from Louisiana (United States) and considered a French founder 
mutation [8]. The p.Arg404Cys mutation occurs at a CpG dinucleotide and is associated with 
four different haplotypes. This substitution is therefore a strong candidate for being recurrent. 
P.Arg404Cys was observed on haplotypes F (in patients from France, Canada, and the US), 
A (France, Italy, and the US), B (France) and D (Germany, US). But all Canadian and US 
American SLOS patients, who are of French origin, carried the p.Arg404Cys on the F 
haplotype. Therefore, it appears possible that p.Arg404Cys originated only once on an F 
haplotype and therefore might also be a founder mutation. 
The p.Gly410Ser is another mutation with a likely founder effect, following two recurrent 
mutational events (Table 4). Further, mutations p.Arg352Trp and p.Arg242His which also 
affect CpG dinucleotides were found to occur on several different haplotypes of which A and 
F were the most frequent ones.  
More than half of the analyzed p.Thr93Met chromosomes could be unambiguously assigned 
to haplotype J. Most of these chromosomes were from Italian and Spanish patients. 
Furthermore, the p.Thr93Met mutation was found to be a frequent mutation on Greek (2 out 
of 4) and Turkish (4 out of 7) SLOS alleles. These findings suggest that many p.Thr93Met 
copies were derived from a founder mutation on a J haplotype in the Mediterranean area. In 
keeping with this suggestion, Cuban SLOS patients have p.Thr93Met on haplotype J as the 
most frequent mutation [41]. P.Thr93Met is also the most common mutation in Brazil [42]. 
Other p.Thr93Met alleles may however be likely to be traced back to a founder mutation on 
haplotype A, which is observed to be associated with many p.Thr93Met chromosomes from 
the UK, Ireland, Germany and the US (of undefined European origins). Since haplotype A is 
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the most frequent haplotype in Europeans, it cannot however be excluded that p.Thr93Met 
has occurred several times on different A haplotypes. P.Thr93Met is also associated with 
other haplotypes in single patients e.g. haplotype F in one Italian and one Spanish patient, 
haplotype C in one Greek and haplotype B in one German patient, respectively. This 
diversity adds further evidence to the supposition that p.Thr93Met is a recurrent mutation in 
Europe, with an obvious founder effect seen in the Mediterranean area.  
The most frequent DHCR7 gene mutations not associated with a CpG are c.964-1G>C, 
p.Val326Leu, and p.Phe302Leu. All of these lesions are only associated with a single 
haplotype each (A or F), suggesting a single mutational origin. On the other hand non-CpG 
mutation p.Trp151X is associated with three different haplotypes, namely F, B, and G, which 
is explicable in terms of marker mutations. Thus, haplotype B differs from haplotype F only at 
position c.1272C>T, and haplotype G carries a polymorphism at position c.1350C>A. The 
ancestors of all p.Trp151X carriers could be traced back to the same area in Poland 
regardless of the haplotype. Hence the mutation is probably older than the SNPs used for 
haplotype construction as many of them are in CpGs. 
 
 
Population Haplotypes 
Typing of European and African DHCR7 wild type alleles revealed that two European 
haplotypes and five African haplotypes accounted for 70% of SLOS alleles in each 
continental group. This result is an additional indication of Africans being a genetically more 
diverse and therefore, “older” population than Europeans. In particular, SLOS-causing 
mutations must have occurred rather recently in the European gene pool. Interestingly, the Z 
haplotype which makes up 14% of African wild-type alleles coincides with the chimpanzee 
sequence with respect to the human SNPs. This might be an indication that the haplotype Z 
is indeed the ancestral haplotype that existed prior to the branching of the two species. The 
coding DNA sequence of Pan differs from that of humans at nine nucleotide positions, 
implying a sequence similarity of 99.4%. This value corresponds well with published data on 
the overall genetic difference between Pan troglodytes and Homo sapiens [43]. 
 
Frequency and Age of Common Mutations 
C.964-1G>C and p.Trp151X are both Null mutations associated with common intragenic 
SNP haplotypes. Hence recurrent origins for both of them can not be completely excluded. 
On the other hand, the fact that each of them is mainly associated with a single haplotype, 
and that both mutations exhibit a characteristic frequency gradient, makes a founder effect 
more likely. The c.964-1G>C lesion has a relatively high carrier frequency throughout Europe 
(ca. 1:100) despite a decrease from North-West to South-Eastern Europe. P.Trp151X has its 
highest frequency (ca. 1:70) in Eastern regions of Europe and is less common in Western 
Europe. The estimated time of first occurrence is approximately 100 generations for both 
mutations. This age estimate may also explain the low prevalence of the SLOS in Finland 
which was settled about 9000 years ago [44] i.e. before the occurrence of the mutation in the 
European gene pool.  
The geographic frequency distribution of the c.964-1G>C resembles that of the CF-causing 
∆F508 mutation in the CFTR gene. The age estimate of ∆F508 ranges from 3000-5200 years 
[45] to 52000 years [46]. These calculations have been criticized on the basis of their 
estimated mutation rate being too low [47,48]. A revised analysis of the data resulted in 
generation numbers of 868 and 145, implying at least a rapprochement to the results of 
Serré et al (1990) [45,47,48]. We may therefore surmise that ∆F508 first arose somewhat 
before the c.964-1G>C in the DHCR7 gene.  
One possible explanation of the high carrier frequency of DHCR7 mutations appears to be 
self-suggesting namely a selective advantage conferred by an excess of 7DHC as a 
precursor of vitamin D in heterozygotes. However, it has been shown recently that serum 
vitamin D levels are not increased in SLOS patients [49] making it unlikely that they are 
elevated in carriers. This renders vitamin D-mediated over-dominance of DHCR7 mutations 
unlikely. Furthermore, over-dominant selection is only required to explain the persistence of 
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old mutations in a gene pool whereas, for recently emerged mutations, random genetic drift 
appears sufficient to explain high mutation frequencies [21,46]. 
It is possible to estimate the number of generations since first appearance of a mutation on 
the basis of carrier frequency data alone, assuming the absence of over-dominant selection. 
In this case, the current carrier frequency qt is approximately equal to 1/t, where t is the 
number of generations elapsed [50]. For c.964-1G>C the average carrier frequency was 
0.84% in 3931 Europeans (Austrian, British, Czech, French, German, Greek, Italian, Polish, 
and Spanish, Table 5), which would correspond to 110 generations since first appearance 
assuming selective neutrality of the heterozygous genotype. Notably, this estimate is well 
consistent with the results of age estimation by LD analysis. Hence the data do not support 
the assumption of over-dominant selection as an explanation for the high frequencies of 
common SLOS mutations. 
 
Based upon the frequency of the two common Null mutations in Europe the expected 
incidence of SLOS patients homozygous or compound heterozygous for these mutations 
would be expected to be 1:5500 with a range of 1:1470 (Austria) to 1:100,000 (Spain). The 
discrepancy between the observed and expected incidence of the SLOS has been explained 
by an embryonic/foetal loss of homozygotes for frequent Null alleles [3,51]. A prenatal 
mortality rate of 80% has been postulated for these genotypes [3,52].  
 
In six of 13 German/Austrian SLOS families, a Polish origin of the ancestral p.Trp151X allele 
has been known. Furthermore, p.Trp151X is the most frequent SLOS mutation in both, the 
Czech Republic (50% of SLOS alleles) and Poland with a strongly decreasing east-west 
gradient [53]. The mutation is therefore likely to have originated in Eastern Europe during the 
Iron Age. Interestingly, a strong westward frequency gradient recently has been reported for 
Y-STR haplogroup I1b* [54]. The authors show that the observed differences between Polish 
and German Y-STR frequencies are probably due to recent migrational events during and, 
particularly shortly after World War II. 
 
The p.Thr93Met mutation is most probably recurrent. Nevertheless, a founder effect 
regarding p.Thr93Met may be evident in the south of Europe. The estimated age of 
p.Thr93Met on the J haplotype is between 5800 and 6200 BC, which is the time of a strong 
east-to-west migration of Neolithic farmers from the Middle East. Interestingly, p.Thr93Met 
(with haplotypes A, C, and J) was also detected to account for two out of four Greek and four 
out of seven Turkish SLOS alleles, which is similar to the situation with PKU mutation 
IVS10nt545 in the PAH gene where a Neolithic origin was proposed [55]. 
 
The resume of our study is that SLOS- causing mutations probably have been propagated by 
a mixture of recurrent mutation, founder events and random drift. Frequent SLOS mutations 
in the European gene pool are relatively young: c.964-1G>C and p.Trp151X probably arose 
only approximately 100 generations ago, p.Thr93Met-J first occurred some 200 generations 
ago. In non-European populations, including Africans and Asians, DHCR7 gene mutations 
are also likely to have emerged but SLOS patients have not been reported except from the 
Middle East. Carriers of c.964-1G>C have been described in Afro-Americans from the US 
and Canada and the mutation was found to be associated with the A haplotype [18]. Knowing 
the considerable European contribution to the Afro-American gene pool, which is estimated 
to be approximately 26%, these c.964-1G>C alleles may well be of European origin [56].  
As has been demonstrated for CF and PKU before, the evolutionary analysis of recessive 
disease mutations, although partly speculative, allows a link to be drawn between genetic 
data and the migration and expansion of different peoples in history. In addition, it may 
contribute to answering the question how recessive diseases became frequent in certain 
populations. In the case of SLOS, the relatively high carrier frequencies of the most common 
mutations were found to be sufficiently explained by interplay of founder effects and genetic 
drift. 
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Figure legend  
Figure 1 Scheme of the DHCR7 gene. Six SNPs used for haplotype construction and 
four flanking microsatellites D11S4139, D11S1314, D11S4207, D11S4119 used for age 
estimation are indicated. Exons (black boxes) are denoted by numbers (1-9). At the top the 
distances of mirosatellites from the gene are indicated according to the physical and the 
recombination maps. 
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